Elite Pharmaceuticals, Inc.
Kirko Kirkov holds extensive experience in the pharmaceutical industry, currently serving as the Chief Commercial Officer at Elite Pharmaceuticals, Inc. Previously, Kirko founded ARCPOINT LABS OF WASHINGTON, DC - SPRING VALLEY and Environmental Project Management AD, and held the position of General Manager for Specialty Generics at Vertice Pharma. Additionally, Kirko had various leadership roles at Sandoz, including Executive Director of the Customer Excellence Team, Executive Director for the Endocrinology Franchise, and Executive Director of Commercial Operations. Kirko's academic background includes a Master's degree in Applied Positive Psychology and Coaching Psychology from the University of East London and an MBA from Durham University.
This person is not in any teams
This person is not in any offices
Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products, to improve off-patent drug products, and developing generic versions of controlled release drug products with high barriers to entry. Elite has four ANDA products partnered with TAGI Pharma; one ANDA has launched, two ANDAs are in the process of a manufacturing site transfer and an additional ANDA is currently under review by the FDA. Elite also manufactures Lodrane D® and receives royalties for Lodrane D®, an allergy product partnered with ECR Pharmaceuticals (“ECR”), a wholly owned subsidiary of Hi-Tech Pharmacal (“Hi-Tech”). Elite’s lead pipeline products, ELI-216, a once-daily abuse resistant oxycodone, and ELI-154, a once-daily oxycodone, are novel sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also has partnered with Mikah Pharma to develop a new product and with Hi-Tech Pharmacal to develop an intermediate for a generic product. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.